44 / 64
Proyecto REHENOVA
36
11. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct
factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb
Haemost. 2010;104:1263-71.
12. Harenberg J, Du S, Krämer S, Giese C, Schulze A, Weiss C, et al. Novel methods for
assessing oral direct factor Xa and thrombin inhibitors: use of point-of-care testing
and urine samples. Semin Thromb Hemost. 2013;39:66-71.
13. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Rever-
sal of rivaroxaban and dabigatran by prothrombin complex concentrate: a rando-
mized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;
124:1573-9.
14. Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T, et al.
Effective elimination of dabigatran by haemodialysis. A phase I single-centre study
in patients with end-stage renal disease. Thromb Haemost. 2013;109:596-605.
15. Zhou W, Zorn M, Nawroth P, Bütehorn U, Perzborn E, Heitmeier S, et al. Hemosta-
tic therapy in experimental intracerebral hemorrhage associated with rivaroxaban.
Stroke. 2013;44:771-8.
16. Marlu R, Hodaj E, Paris A,Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific
reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised
crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108:217-24.
17. Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, Roquer J, Reverter JC, Sanz VV,
et al. Reversal of apixaban induced alterations in hemostasis by different coagulation
factor concentrates: significance of studies in vitro with circulating human blood.
PLoS One. 2013;11;8:e78696.
18. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, et al. A specific
antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation
factor Xa. Nat Med. 2013;19:446-51.
19. Escolar Albadalejo G, García Frade J, Lopez Fernandez MF, Roldán Schillling V. Guía
sobre los nuevos anticoagulantes orales. Sociedad Española de Hematología y Hemo-
terapia/Sociedad Española de Trombosis y Hemostasia. Disponible en:
http://www.sehh.es/es/documentos/guias-y-documentos/1747-guia-sehh-seth-para-el-mane-
jo-de-los-nuevos-anticoagulantes-orales.html
20. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral
anticoagulants. Eur Heart J. 2013;34:489-98b.